anti-HER2 dendritic cell vaccine

{
  "id": "MLC-T-ONC-010746",
  "term": "anti-HER2 dendritic cell vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A type-1-polarized dendritic cell (DC1)-based cancer vaccine against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2), with potential immunomodulatory and antineoplastic activities. Upon intratumoral administration of the anti-HER2 DC vaccine, the immune system gets exposed to HER2, which may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER2-positive tumor cells. This may result in tumor cell death and decreased tumor growth. HER2, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is overexpressed by a variety of cancers.",
  "synonyms": [
    "anti-HER-2 DC vaccine",
    "anti-HER2 DC vaccine",
    "anti-HER2 DC1 vaccine",
    "HER2-primed DC vaccine",
    "HER2-primed DC1 vaccine",
    "HER2-primed dendritic cell vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-her2-dendritic-cell-vaccine/"
}